



eureKING

Press release

Availability of the 2022 Annual Financial Report

Paris, France, April 28, 2023 – eureKING (Euronext Paris - mnémonique: KINGS – ISIN: FR0014009ON9), the first European SPAC in healthcare dedicated to biomanufacturing, today announced that its annual financial report for the period ending December 31st, 2022 is now available and has been filed with the French Financial Markets Authority (*Autorité des marchés financiers*). This document is available on eureKING website www.eureking.com in the Investors section.

About eureKING: eureking.com

Founded in March 2022, eureKING is a French SPAC (Special Purpose Acquisition Company) formed with the aim of acquiring European companies in the field of biomanufacturing, with the ambition of creating a leading bio-CDMO in Europe capable of meeting the growing outsourcing needs of this industry.

eureKING has chosen to focus on three highly specialized and strategic segments of the biopharmaceutical industry: the production of biologics, in particular new generations of monoclonal antibodies or complex proteins, the production of cell and gene therapies and the production of live biotherapeutics (with applications in the microbiome).

Led by an international management team of experienced healthcare industry talent, 100% dedicated to the eureKING project and its development strategy, and supported by a Board of Directors with complementary skills in the pharmaceutical and financial fields, eureKING aims at developing and promoting the promising biomanufacturing sector in Europe on an international scale.

Contacts:

eureKING

info@eureking.com

Image 7

Leslie Jung-Isenwater / Sergio de la Calle
+33 (0)1 53 70 74 70 / eureking@image7.fr